Citadel Advisors’s Apyx Medical APYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $756K | Buy |
168,344
+60,546
| +56% | +$240K | ﹤0.01% | 8886 |
|
|
2026
Q1 | $398K | Buy |
+107,798
| New | +$403K | ﹤0.01% | 9825 |
|
|
2025
Q4 | – | Sell |
-13,292
| Closed | -$28.4K | – | 12594 |
|
|
2025
Q3 | $28.4K | Buy |
+13,292
| New | +$28.1K | ﹤0.01% | 12414 |
|
|
2025
Q2 | – | Sell |
-13,566
| Closed | -$18.6K | – | 12426 |
|
|
2025
Q1 | $18.6K | Sell |
13,566
-52,789
| -80% | -$72.7K | ﹤0.01% | 13196 |
|
|
2024
Q4 | $105K | Buy |
66,355
+53,782
| +428% | +$75.2K | ﹤0.01% | 11421 |
|
|
2024
Q3 | $15.6K | Buy |
12,573
+9,297
| +284% | +$11.7K | ﹤0.01% | 12963 |
|
|
2024
Q2 | $4.39K | Buy |
+3,276
| New | +$4.83K | ﹤0.01% | 13490 |
|
|
2024
Q1 | – | Sell |
-59,785
| Closed | -$127K | – | 14509 |
|
|
2023
Q4 | $157K | Buy |
59,785
+45,329
| +314% | +$110K | ﹤0.01% | 10319 |
|
|
2023
Q3 | $46.3K | Buy |
14,456
+11,791
| +442% | +$54.9K | ﹤0.01% | 11839 |
|
|
2023
Q2 | $13.4K | Sell |
2,665
-111,168
| -98% | -$563K | ﹤0.01% | 13043 |
|
|
2023
Q1 | $328K | Buy |
113,833
+38,578
| +51% | +$113K | ﹤0.01% | 9199 |
|
|
2022
Q4 | $176K | Buy |
75,255
+59,279
| +371% | +$181K | ﹤0.01% | 10358 |
|
|
2022
Q3 | $72K | Sell |
15,976
-79,156
| -83% | -$567K | ﹤0.01% | 11352 |
|
|
2022
Q2 | $557K | Buy |
+95,132
| New | +$488K | ﹤0.01% | 8410 |
|
|
2022
Q1 | – | Sell |
-32,044
| Closed | -$411K | – | 13515 |
|
|
2021
Q4 | $411K | Sell |
32,044
-17,722
| -36% | -$248K | ﹤0.01% | 10144 |
|
|
2021
Q3 | $689K | Sell |
49,766
-13,138
| -21% | -$138K | ﹤0.01% | 9111 |
|
|
2021
Q2 | $649K | Buy |
62,904
+42,071
| +202% | +$417K | ﹤0.01% | 9420 |
|
|
2021
Q1 | $202K | Buy |
+20,833
| New | +$208K | ﹤0.01% | 11680 |
|
|
2020
Q2 | – | Sell |
-20,875
| Closed | -$75K | – | 9727 |
|
|
2020
Q1 | $75K | Buy |
+20,875
| New | +$140K | ﹤0.01% | 8818 |
|
|
2019
Q2 | – | Sell |
-18,201
| Closed | -$115K | – | 9125 |
|
|
2019
Q1 | $115K | Sell |
18,201
-23,233
| -56% | -$180K | ﹤0.01% | 8493 |
|
|
2018
Q4 | $268K | Buy |
41,434
+26,661
| +180% | +$161K | ﹤0.01% | 7446 |
|
|
2018
Q3 | $105K | Buy |
+14,773
| New | +$82.1K | ﹤0.01% | 8553 |
|
|
2017
Q3 | – | Sell |
-11,957
| Closed | -$30K | – | 7495 |
|
|
2017
Q2 | $30K | Buy |
+11,957
| New | +$29.4K | ﹤0.01% | 7200 |
|
|
2017
Q1 | – | Sell |
-11,951
| Closed | -$43K | – | 7399 |
|
|
2016
Q4 | $43K | Buy |
+11,951
| New | +$53.2K | ﹤0.01% | 6897 |
|
|
2016
Q2 | – | Sell |
-10,964
| Closed | -$18K | – | 6788 |
|
|
2016
Q1 | $18K | Buy |
+10,964
| New | +$22.1K | ﹤0.01% | 6490 |
|
Other funds holding APYX
RA
NCM
ACM
EIM
ACM
SBCM
HKAM
Citadel Advisors's APYX Position: Q2 2026 in Review
Citadel Advisors increased its Apyx Medical (APYX) stake by 56% in Q2 2026, buying an estimated $240K and bringing the position to 168,344 shares worth $756K. The position accounts for ﹤0.01% of the portfolio, ranked #8886.
Citadel Advisors first reported a position in APYX in Q1 2016 and has held it in 25 quarters since. 68 funds tracked by Wall St. Rank hold APYX as of Q2 2026.
- Citadel Advisors held 168,344 shares of Apyx Medical worth $756K as of Q2 2026.
- Citadel Advisors bought 60,546 Apyx Medical shares in Q2 2026, an estimated $240K.
- Apyx Medical made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8886 holding.
- Citadel Advisors first reported a position in Apyx Medical in Q1 2016 and has held it in 25 quarters since.
- 68 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.